サンプル依頼リスト カート
  • English
  • Korean
表紙：モノクローナル抗体（mAb）の世界市場レポート2023年版
市場調査レポート
商品コード
1210218

モノクローナル抗体（mAb）の世界市場レポート2023年版

Monoclonal Antibodies (MAbS) Global Market Report 2023
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.42円
モノクローナル抗体（mAb）の世界市場レポート2023年版
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

世界のモノクローナル抗体（mAb）市場は、2021年の1,687億米ドルから2022年には年平均成長率（CAGR）11.5％で1,881億8,000万米ドルに成長すると予測されています。ロシア・ウクライナ戦争は、少なくとも短期的にはCOVID-19のパンデミックからの世界経済回復の可能性を混乱させました。この2国間の戦争は、複数の国に対する経済制裁、商品価格の高騰、サプライチェーンの混乱につながり、商品やサービス全体にインフレを引き起こし、世界中の多くの市場に影響を及ぼしています。同市場は、2026年にはCAGR11.6%で2,922億2,000万米ドルに達すると予測されています。

モノクローナル抗体（mAb）市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 モノクローナル抗体（mAb）市場の特徴

第3章 モノクローナル抗体（mAb）市場の動向と戦略

第4章 モノクローナル抗体（mAb）市場- マクロ経済シナリオ

第4章 1 COVID-19がモノクローナル抗体（mAb）市場に与える影響

第4章 2ウクライナとロシアの戦争がモノクローナル抗体（mAb）市場に与える影響

第4章 3モノクローナル抗体（mAb）市場に対する高インフレの影響

第5章 モノクローナル抗体（mAb）の市場規模と成長

  • 世界のモノクローナル抗体（mAb）市場の実績、2017～2022年
    • 市場の促進要因
    • 市場の抑制要因
  • 世界のモノクローナル抗体（mAb）市場の予測、2022-2027F、2032F
    • 市場の促進要因
    • 市場の抑制要因

第6章 モノクローナル抗体（mAb）市場セグメンテーション

  • 世界のモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • ネズミ
  • キメラ
  • ヒト化
  • 人間
  • 世界のモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 抗がん剤
  • 免疫学
  • 抗感染性モノクローナル抗体（Mab）
  • 神経薬理学
  • 心血管および脳血管
  • その他
  • 世界のモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 病院
  • プライベートクリニック
  • 調査

第7章 モノクローナル抗体（mAb）市場の地域および国の分析

  • 世界のモノクローナル抗体（mAb）市場、地域別、実績と予測、2017-2022、2022-2027F、2032F
  • 世界のモノクローナル抗体（mAb）市場、国別、実績と予測、2017-2022、2022-2027F、2032F

第8章 アジア太平洋モノクローナル抗体（mAb）市場

  • アジア太平洋のモノクローナル抗体（mAb）市場概要
  • 地域情報, COVID-19の影響,市場情報,背景情報,政府のイニシアチブ,規制,規制機関,主要団体,課税される税,法人税構造,投資,主要企業
  • アジア太平洋のモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • アジア太平洋のモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • アジア太平洋のモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第9章 中国のモノクローナル抗体（mAb）市場

  • 中国のモノクローナル抗体（mAb）市場概要
  • 中国モノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 中国のモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 中国のモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第10章 インドのモノクローナル抗体（mAb）市場

  • インドのモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • インドのモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • インドのモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第11章 日本のモノクローナル抗体（mAb）市場

  • 日本のモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 日本のモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 日本のモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第12章 オーストラリアのモノクローナル抗体（mAb）市場

  • オーストラリアのモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • オーストラリアのモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • オーストラリアのモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第13章 インドネシアのモノクローナル抗体（mAb）市場

  • インドネシアのモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • インドネシアのモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • インドネシアのモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第14章 韓国のモノクローナル抗体（mAb）市場

  • 韓国のモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 韓国のモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 韓国のモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第15章 西欧のモノクローナル抗体（mAb）市場

  • 西欧のモノクローナル抗体（mAb）市場概要
  • 西欧のモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 西欧のモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 西欧のモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第16章 英国のモノクローナル抗体（mAb）市場

  • 英国モノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 英国モノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 英国モノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第17章 ドイツのモノクローナル抗体（mAb）市場

  • ドイツのモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • ドイツのモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • ドイツのモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第18章 フランスのモノクローナル抗体（mAb）市場

  • フランスのモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • フランスのモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • フランスのモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第19章 東欧のモノクローナル抗体（mAb）市場

  • 東欧のモノクローナル抗体（mAb）市場概要
  • 東欧のモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 東欧のモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 東欧のモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第20章 ロシアのモノクローナル抗体（mAb）市場

  • ロシアのモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • ロシアのモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • ロシアのモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第21章 北米モノクローナル抗体（mAb）市場

  • 北米モノクローナル抗体（mAb）市場概要
  • 北米モノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 北米モノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 北米モノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第22章 米国のモノクローナル抗体（mAb）市場

  • 米国モノクローナル抗体（mAb）市場概要
  • 米国モノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 米国モノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 米国モノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第23章 南米のモノクローナル抗体（mAb）市場

  • 南米モノクローナル抗体（mAb）市場概要
  • 南米のモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 南米のモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 南米のモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第24章 ブラジルのモノクローナル抗体（mAb）市場

  • ブラジルのモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • ブラジルのモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • ブラジルのモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第25章 中東モノクローナル抗体（mAb）市場

  • 中東モノクローナル抗体（mAb）市場概要
  • 中東モノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 中東モノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • 中東モノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第26章 アフリカのモノクローナル抗体（mAb）市場

  • アフリカモノクローナル抗体（mAb）市場概要
  • アフリカモノクローナル抗体（mAb）市場、ソース別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • アフリカのモノクローナル抗体（mAb）市場、アプリケーション別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • アフリカモノクローナル抗体（mAb）市場、エンドユーザー別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第27章 モノクローナル抗体（mAb）市場の競合情勢環境と企業プロファイル

  • モノクローナル抗体（mAb）市場の競合情勢環境
  • モノクローナル抗体（mAb）市場の企業プロファイル
    • Johnson &Johnson
    • Merck
    • AbbVie
    • Amgen
    • Glaxosmithkline plc

第28章 モノクローナル抗体（mAb）パイプライン分析

第29章 モノクローナル抗体（mAb）市場における主要な合併と買収

第30章 モノクローナル抗体（mAb）市場の将来の見通しと潜在的な分析

第31章 付録

目次
Product Code: r2071

“Monoclonal Antibodies (MAbS) Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on monoclonal antibodies (mabs) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for monoclonal antibodies (mabs) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The monoclonal antibodies (mabs) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Source: Murine; Chimeric; Humanized; Human
  • 2) By Application: Anti-Cancer; Immunological; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological; Cardiovascular And Cerebrovascular; Other Applications
  • 3) By End Users: Hospitals; Private Clinics; Research Institute
  • Companies Mentioned: Johnson & Johnson; Merck; AbbVie; Amgen; Glaxosmithkline plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the monoclonal antibodies (MABS) market are: Johnson & Johnson, Merck, AbbVie, Amgen, GlaxoSmithKline plc., Norvatis AG, Pfizer Inc, Thermofischer Scientific, Elililly and Company and Bristol-Myers Squibb.

The global monoclonal antibodies (MAbs) market is expected to grow from $168.70 billion in 2021 to $188.18 billion in 2022 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The market is expected to reach $292.22 billion in 2026 at a CAGR of 11.6%.

The monoclonal antibodies (MABS) market consists of sales of rituximab, cetuximab, and trastuzumab. Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Monoclonal antibodies (MABS) refer to a laboratory-produced proteins intended to boost your immune system. Treatments for monoclonal antibodies are often administered as IV solutions, frequently in an infusion center. A component of your immune system are antibodies. To kill them, they seek out the antigens (foreign substances) and adhere to them.

The main types of sources in monoclonal antibodies (MABS) are murine, chimeric, humanized, and human. A murine antibody has two types of chains, one of which is from a mouse and the other from a human. The pre-stem -o- in a murine antibody's INN is used to identify it. It is used in anti-cancer, immunological, anti-infective monoclonal antibodies (MAbs), neuropharmacological, cardiovascular and cerebrovascular, and others and implemented in various sectors such as hospitals, private clinics, and research institutes.

The Increasing prevalence of cost-efficient biosimilar monoclonal antibodies is driving the monoclonal antibodies market growth. The biosimilar aim is to curb the increasing healthcare cost and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilar is the pharmaceuticals that are developed to have similar properties to a biological drug that has already been approved. A biosimilar monoclonal antibody costs 20%-25% lesser than the originator biologic drug. The number of clinical trials for a biosimilar is comparatively lesser than that of the original biologic drug and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the 'Guidelines on Similar Biologics' prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.

Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to hurt the revenues of the monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue of US retail sales of homeopathic and herbal remedies was around $7.5 billion. These less expensive alternatives increase the competitiveness of the biologics market putting downward pressure and limiting the demand for monoclonal antibody drugs.

The monoclonal antibody market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden their products and services. Strategic collaborations, acquisitions, and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, in March 2022, Sanofi S.A., a France based pharmaceutical and healthcare company specializing in the discovery, development, manufacturing, and commercialization of drugs, announced a strategic collaboration with Seagen Inc., a US-based pharmaceutical company specializing in the development and commercialization of novel, powerful monoclonal antibody-based cancer treatments. Under this agreement, the partnership will use Seagen's and Sanofi's exclusive monoclonal antibody (mAb) and antibody-drug conjugate (ADC) technologies to design, develop, and market ADCs for up to three cancer targets. Furthermore, Boehringer Ingelheim, a Germany-based research-driven pharmaceutical company, announced a collaboration with MabGenesis, Inc., a Japan-based biopharmaceutical company pioneering in the development of therapeutic monoclonal antibody drugs for the treatment of human diseases. Through this collaboration, Boehringer Ingelheim and MabGenesis discover and develop novel therapeutic monoclonal antibodies for the treatment of various diseases and strategic research and development strategies. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally.

The food and drug administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA regulating the monoclonal antibodies and pharmaceutical drugs market. Increasing product launches and regulatory support for the treatment of rare diseases by the USFDA are expected to support the monoclonal antibody therapeutics market growth. For instance, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease, metastatic Merkel cell carcinoma (MCC). Similarly, the U.S FDA granted accelerated approval to the immunotherapy product- TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, for the treatment of people with locally-advanced or metastatic urothelial carcinoma (MUC).

The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the monoclonal antibodies (MABS) market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The monoclonal antibodies (MABS) market research report is one of a series of new reports from The Business Research Company that provides monoclonal antibodies (MABS) market statistics, including monoclonal antibodies (MABS) industry global market size, regional shares, competitors with a monoclonal antibodies (MABS) market share, detailed monoclonal antibodies (MABS) market segments, market trends and opportunities, and any further data you may need to thrive in the monoclonal antibodies (MABS) industry. This monoclonal antibody (MABS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Table of Contents

1. Executive Summary

2. Monoclonal Antibodies (MAbS) Market Characteristics

3. Monoclonal Antibodies (MAbS) Market Trends And Strategies

4. Monoclonal Antibodies (MAbS) Market - Macro Economic Scenario

4.1 COVID-19 Impact On Monoclonal Antibodies (MAbS) Market

4.2 Ukraine-Russia War Impact On Monoclonal Antibodies (MAbS) Market

4.3 Impact Of High Inflation On Monoclonal Antibodies (MAbS) Market

5. Monoclonal Antibodies (MAbS) Market Size And Growth

  • 5.1. Global Monoclonal Antibodies (MAbS) Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Monoclonal Antibodies (MAbS) Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Monoclonal Antibodies (MAbS) Market Segmentation

  • 6.1. Global Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Murine
  • Chimeric
  • Humanized
  • Human
  • 6.2. Global Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Anti-Cancer
  • Immunological
  • Anti-Infective Monoclonal Antibodies (Mabs)
  • Neuropharmacological
  • Cardiovascular And Cerebrovascular
  • Others
  • 6.3. Global Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospitals
  • Private Clinics
  • Research Institute

7. Monoclonal Antibodies (MAbS) Market Regional And Country Analysis

  • 7.1. Global Monoclonal Antibodies (MAbS) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Monoclonal Antibodies (MAbS) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Monoclonal Antibodies (MAbS) Market

  • 8.1. Asia-Pacific Monoclonal Antibodies (MAbS) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 8.3. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 8.4. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Monoclonal Antibodies (MAbS) Market

  • 9.1. China Monoclonal Antibodies (MAbS) Market Overview
  • 9.2. China Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
  • 9.3. China Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
  • 9.4. China Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Monoclonal Antibodies (MAbS) Market

  • 10.1. India Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 10.2. India Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 10.3. India Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Monoclonal Antibodies (MAbS) Market

  • 11.1. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 11.2. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 11.3. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Monoclonal Antibodies (MAbS) Market

  • 12.1. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 12.2. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 12.3. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Monoclonal Antibodies (MAbS) Market

  • 13.1. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 13.2. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 13.3. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Monoclonal Antibodies (MAbS) Market

  • 14.1. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 14.2. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 14.3. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Monoclonal Antibodies (MAbS) Market

  • 15.1. Western Europe Monoclonal Antibodies (MAbS) Market Overview
  • 15.2. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 15.3. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 15.4. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Monoclonal Antibodies (MAbS) Market

  • 16.1. UK Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 16.2. UK Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 16.3. UK Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Monoclonal Antibodies (MAbS) Market

  • 17.1. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 17.2. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 17.3. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Monoclonal Antibodies (MAbS) Market

  • 18.1. France Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 18.2. France Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 18.3. France Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Monoclonal Antibodies (MAbS) Market

  • 19.1. Eastern Europe Monoclonal Antibodies (MAbS) Market Overview
  • 19.2. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 19.3. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 19.4. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Monoclonal Antibodies (MAbS) Market

  • 20.1. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 20.2. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 20.3. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Monoclonal Antibodies (MAbS) Market

  • 21.1. North America Monoclonal Antibodies (MAbS) Market Overview
  • 21.2. North America Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 21.3. North America Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 21.4. North America Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Monoclonal Antibodies (MAbS) Market

  • 22.1. USA Monoclonal Antibodies (MAbS) Market Overview
  • 22.2. USA Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 22.3. USA Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 22.4. USA Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Monoclonal Antibodies (MAbS) Market

  • 23.1. South America Monoclonal Antibodies (MAbS) Market Overview
  • 23.2. South America Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 23.3. South America Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 23.4. South America Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Monoclonal Antibodies (MAbS) Market

  • 24.1. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 24.2. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 24.3. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Monoclonal Antibodies (MAbS) Market

  • 25.1. Middle East Monoclonal Antibodies (MAbS) Market Overview
  • 25.2. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 25.3. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 25.4. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Monoclonal Antibodies (MAbS) Market

  • 26.1. Africa Monoclonal Antibodies (MAbS) Market Overview
  • 26.2. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 26.3. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 26.4. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Monoclonal Antibodies (MAbS) Market Competitive Landscape And Company Profiles

  • 27.1. Monoclonal Antibodies (MAbS) Market Competitive Landscape
  • 27.2. Monoclonal Antibodies (MAbS) Market Company Profiles
    • 27.2.1. Johnson & Johnson
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Merck
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. AbbVie
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Amgen
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Glaxosmithkline plc
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Monoclonal Antibodies (MAbS) Pipeline Analysis

29. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAbS) Market

30. Monoclonal Antibodies (MAbS) Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Historic And Forecast Inflation Rates
  • 31.4. Research Inquiries
  • 31.5. The Business Research Company
  • 31.6. Copyright And Disclaimer